NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.45+0.30 (+13.95%)
Close on Nov 17, 2026Market cap $106.08MP/E –Yield –
NRX Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
NRX Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.41M, up 57.4% year over year. For fiscal 2025 it was $3.78M, down 39.1% from the year before. The highest annual figure on record is $20.26M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.78M | -39.1% |
| FY2024 | Dec 31, 2024 | $6.20M | -53.6% |
| FY2023 | Dec 31, 2023 | $13.37M | -21.5% |
| FY2022 | Dec 31, 2022 | $17.03M | -15.9% |
| FY2021 | Dec 31, 2021 | $20.26M | +90.7% |
| FY2020 | Dec 31, 2020 | $10.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.12M | +114.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.31M | +62.8% |
| Q4 FY2025 | Dec 31, 2025 | $558.00K | -46.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.43M | +133.9% |
| Q2 FY2025 | Jun 30, 2025 | $987.00K | -64.8% |
| Q1 FY2025 | Mar 31, 2025 | $804.00K | -54.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.04M | -59.1% |
| Q3 FY2024 | Sep 30, 2024 | $611.00K | -81.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.80M | -27.6% |
| Q1 FY2024 | Mar 31, 2024 | $1.75M | +117.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.53M | -43.1% |
| Q3 FY2023 | Sep 30, 2023 | $3.31M | -19.7% |
| Q2 FY2023 | Jun 30, 2023 | $3.87M | +30.9% |
| Q1 FY2023 | Mar 31, 2023 | $804.00K | -85.3% |
| Q4 FY2022 | Dec 31, 2022 | $4.46M | -30.5% |
| Q3 FY2022 | Sep 30, 2022 | $4.13M | -34.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.96M | -36.5% |
| Q1 FY2022 | Mar 31, 2022 | $5.48M | +88.5% |
| Q4 FY2021 | Dec 31, 2021 | $6.41M | +49.2% |
| Q3 FY2021 | Sep 30, 2021 | $6.28M | +44.9% |
| Q2 FY2021 | Jun 30, 2021 | $4.66M | +235.1% |
| Q1 FY2021 | Mar 31, 2021 | $2.91M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.30M | – |
| Q3 FY2020 | Sep 30, 2020 | $4.33M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.39M | – |
See a number that looks wrong?